Experimental combo targets Hard-to-Treat bone cancer

NCT ID NCT06438783

Terminated Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—TQB2928 (an antibody that helps the immune system attack cancer cells) and anlotinib (a drug that cuts off tumor blood supply)—in 20 people with advanced osteosarcoma or other solid tumors that had stopped responding to standard treatments. The study aimed to see if the combination was safe and could slow cancer growth. However, the trial was terminated early, so results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2928 injection (a lab-made antibody targeting CD47) plus anlotinib hydrochloride capsule (a cancer drug that blocks blood vessel growth)
What this could lead to: If this combination works, it could offer a new treatment option for people with advanced osteosarcoma or other solid tumors that have stopped responding to standard therapy.
What could go wrong: This is a very early (Phase 1) trial with only 20 participants, so results may not apply to larger groups. The trial was terminated early, and the combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED LIPOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dedifferentiated liposarcoma neoplasm osteosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OSTEOSARCOMA OTHER SOLID TUMORS

Contacts and locations

Locations

Beijing cancer hospital

Beijing, Beijing Municipality, 100142, China
Beijing jishuitan hospital

Beijing, Beijing Municipality, 100035, China
Hunan cancer hospital

Changsha, Hunan, 410031, China
Pekjing university people's hospital

Beijing, Beijing Municipality, 100044, China
Tianjin medical university cancer institute&hospital

Tianjin, Tianjin Municipality, 300181, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.